Japan Recommends First PCSK9 Inhibitor
This article was originally published in PharmAsia News
Japan has issued a positive approval recommendation for the first PCSK9-targeting biologic in the country, Amgen Astellas BioPharma's Repatha, which now looks set to reach the market early next year.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.